On August 10, GENSCRIPT BIO rose 5.83% in regular trading, trading at HKD 23.52/share, with turnover of HKD 217 million, extending its recent strong performance.

On the news front, the company's associate Legend Biotech reported CARVYKTI net trade sales of approximately $657 million in Q2, representing a 49.4% year-over-year increase and 10% sequential growth. First-half sales reached $1.254 billion, up 55.1% year-over-year. Meanwhile, the company will hold a board meeting on August 15 to review and approve interim results for the six months ended June 30 and consider interim dividend distribution, with market expectations remaining optimistic.

The broader CXO sector has also been strengthening, with WuXi AppTec reporting approximately 89% year-over-year growth in adjusted net profit for the first half, boosting overall industry sentiment. These multiple positive catalysts have collectively propelled the stock higher.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)